Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor

SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen...

Full description

Saved in:
Bibliographic Details
Published in:International cancer conference journal 2021-04, Vol.10 (2), p.112-115
Main Authors: Tanaka, Shigeru, Hayashi, Shuhei, Isobe, Yoshitaka, Maruyama, Eiichi, Ozawa, Hiroaki, Okuno, Motoyasu, Kondo, Masaru
Format: Article
Language:English
Subjects:
Cancer therapies
Carboplatin
Case Report
Chemotherapy
Consent
Emphysema
Genomes
Immunotherapy
Lung cancer
Malignancy
Medical imaging
Medicine
Medicine & Public Health
Morphology
Mutation
Oncology
Ovaries
Pembrolizumab
Pleural effusion
Sarcoma
Surgical Oncology
Thorax
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513
cites cdi_FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513
container_end_page 115
container_issue 2
container_start_page 112
container_title International cancer conference journal
container_volume 10
creator Tanaka, Shigeru
Hayashi, Shuhei
Isobe, Yoshitaka
Maruyama, Eiichi
Ozawa, Hiroaki
Okuno, Motoyasu
Kondo, Masaru
description SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.
doi_str_mv 10.1007/s13691-021-00472-4
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7947161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507670559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513</originalsourceid><addsrcrecordid>eNp9kUtLxDAUhYMojoz-ARdScOOmmkfbNBthGHyBovhYuAppHhppmzFJB-bfGx0dHwsX4QbOd8-9lwPALoKHCEJ6FBCpGMohTg8WFOfFGtjCiOGcoJqs__iPwE4ILxBCDAsG62oTjAihdYXrcgs83rhgo53rzA1Rui5VkxnrQ8xb2-ssPmsvZovMOJ-J7O5qcjudFLnSxkqr-5h054W0MgvCp3YRnVVZHDrnt8GGEW3QO591DB5OT-6n5_nl9dnFdHKZy4IVMTdSa2EwVhXEQhFEmFClMEwpalhljKa1aqiBJZZKNsyosmGs0tgw2VBZIjIGx0vf2dB0Wsm0lRctn3nbCb_gTlj-W-ntM39yc05ZQVH1bnDwaeDd66BD5J0NUret6LUbAsclpBWFZckSuv8HfXGD79N5HDPEkl0N60ThJSW9C8Frs1oGQf4eHl-Gx1N4_CM8XqSmvZ9nrFq-okoAWQIhSf2T9t-z_7F9AzC9pxU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919716808</pqid></control><display><type>article</type><title>Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor</title><source>Springer Link</source><source>PubMed Central</source><creator>Tanaka, Shigeru ; Hayashi, Shuhei ; Isobe, Yoshitaka ; Maruyama, Eiichi ; Ozawa, Hiroaki ; Okuno, Motoyasu ; Kondo, Masaru</creator><creatorcontrib>Tanaka, Shigeru ; Hayashi, Shuhei ; Isobe, Yoshitaka ; Maruyama, Eiichi ; Ozawa, Hiroaki ; Okuno, Motoyasu ; Kondo, Masaru</creatorcontrib><description>SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.</description><identifier>ISSN: 2192-3183</identifier><identifier>EISSN: 2192-3183</identifier><identifier>DOI: 10.1007/s13691-021-00472-4</identifier><identifier>PMID: 33786285</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Cancer therapies ; Carboplatin ; Case Report ; Chemotherapy ; Consent ; Emphysema ; Genomes ; Immunotherapy ; Lung cancer ; Malignancy ; Medical imaging ; Medicine ; Medicine &amp; Public Health ; Morphology ; Mutation ; Oncology ; Ovaries ; Pembrolizumab ; Pleural effusion ; Sarcoma ; Surgical Oncology ; Thorax ; Tumors</subject><ispartof>International cancer conference journal, 2021-04, Vol.10 (2), p.112-115</ispartof><rights>The Japan Society of Clinical Oncology 2021</rights><rights>The Japan Society of Clinical Oncology 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513</citedby><cites>FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513</cites><orcidid>0000-0003-0825-6919</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947161/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947161/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33786285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Shigeru</creatorcontrib><creatorcontrib>Hayashi, Shuhei</creatorcontrib><creatorcontrib>Isobe, Yoshitaka</creatorcontrib><creatorcontrib>Maruyama, Eiichi</creatorcontrib><creatorcontrib>Ozawa, Hiroaki</creatorcontrib><creatorcontrib>Okuno, Motoyasu</creatorcontrib><creatorcontrib>Kondo, Masaru</creatorcontrib><title>Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor</title><title>International cancer conference journal</title><addtitle>Int Canc Conf J</addtitle><addtitle>Int Cancer Conf J</addtitle><description>SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.</description><subject>Cancer therapies</subject><subject>Carboplatin</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Consent</subject><subject>Emphysema</subject><subject>Genomes</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Malignancy</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Morphology</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Ovaries</subject><subject>Pembrolizumab</subject><subject>Pleural effusion</subject><subject>Sarcoma</subject><subject>Surgical Oncology</subject><subject>Thorax</subject><subject>Tumors</subject><issn>2192-3183</issn><issn>2192-3183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kUtLxDAUhYMojoz-ARdScOOmmkfbNBthGHyBovhYuAppHhppmzFJB-bfGx0dHwsX4QbOd8-9lwPALoKHCEJ6FBCpGMohTg8WFOfFGtjCiOGcoJqs__iPwE4ILxBCDAsG62oTjAihdYXrcgs83rhgo53rzA1Rui5VkxnrQ8xb2-ssPmsvZovMOJ-J7O5qcjudFLnSxkqr-5h054W0MgvCp3YRnVVZHDrnt8GGEW3QO591DB5OT-6n5_nl9dnFdHKZy4IVMTdSa2EwVhXEQhFEmFClMEwpalhljKa1aqiBJZZKNsyosmGs0tgw2VBZIjIGx0vf2dB0Wsm0lRctn3nbCb_gTlj-W-ntM39yc05ZQVH1bnDwaeDd66BD5J0NUret6LUbAsclpBWFZckSuv8HfXGD79N5HDPEkl0N60ThJSW9C8Frs1oGQf4eHl-Gx1N4_CM8XqSmvZ9nrFq-okoAWQIhSf2T9t-z_7F9AzC9pxU</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Tanaka, Shigeru</creator><creator>Hayashi, Shuhei</creator><creator>Isobe, Yoshitaka</creator><creator>Maruyama, Eiichi</creator><creator>Ozawa, Hiroaki</creator><creator>Okuno, Motoyasu</creator><creator>Kondo, Masaru</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0825-6919</orcidid></search><sort><creationdate>20210401</creationdate><title>Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor</title><author>Tanaka, Shigeru ; Hayashi, Shuhei ; Isobe, Yoshitaka ; Maruyama, Eiichi ; Ozawa, Hiroaki ; Okuno, Motoyasu ; Kondo, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer therapies</topic><topic>Carboplatin</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Consent</topic><topic>Emphysema</topic><topic>Genomes</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Malignancy</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Morphology</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Ovaries</topic><topic>Pembrolizumab</topic><topic>Pleural effusion</topic><topic>Sarcoma</topic><topic>Surgical Oncology</topic><topic>Thorax</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Shigeru</creatorcontrib><creatorcontrib>Hayashi, Shuhei</creatorcontrib><creatorcontrib>Isobe, Yoshitaka</creatorcontrib><creatorcontrib>Maruyama, Eiichi</creatorcontrib><creatorcontrib>Ozawa, Hiroaki</creatorcontrib><creatorcontrib>Okuno, Motoyasu</creatorcontrib><creatorcontrib>Kondo, Masaru</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International cancer conference journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Shigeru</au><au>Hayashi, Shuhei</au><au>Isobe, Yoshitaka</au><au>Maruyama, Eiichi</au><au>Ozawa, Hiroaki</au><au>Okuno, Motoyasu</au><au>Kondo, Masaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor</atitle><jtitle>International cancer conference journal</jtitle><stitle>Int Canc Conf J</stitle><addtitle>Int Cancer Conf J</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>10</volume><issue>2</issue><spage>112</spage><epage>115</epage><pages>112-115</pages><issn>2192-3183</issn><eissn>2192-3183</eissn><abstract>SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>33786285</pmid><doi>10.1007/s13691-021-00472-4</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-0825-6919</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2192-3183
ispartof International cancer conference journal, 2021-04, Vol.10 (2), p.112-115
issn 2192-3183
2192-3183
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7947161
source Springer Link; PubMed Central
subjects Cancer therapies
Carboplatin
Case Report
Chemotherapy
Consent
Emphysema
Genomes
Immunotherapy
Lung cancer
Malignancy
Medical imaging
Medicine
Medicine & Public Health
Morphology
Mutation
Oncology
Ovaries
Pembrolizumab
Pleural effusion
Sarcoma
Surgical Oncology
Thorax
Tumors
title Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T19%3A12%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Positive%20outcome%20of%20first-line%20therapy%20for%20a%20SMARCA4-deficient%20thoracic%20sarcomatoid%20tumor&rft.jtitle=International%20cancer%20conference%20journal&rft.au=Tanaka,%20Shigeru&rft.date=2021-04-01&rft.volume=10&rft.issue=2&rft.spage=112&rft.epage=115&rft.pages=112-115&rft.issn=2192-3183&rft.eissn=2192-3183&rft_id=info:doi/10.1007/s13691-021-00472-4&rft_dat=%3Cproquest_pubme%3E2507670559%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-fceeaf22d602ad3139ad5af9dd7f96ffe78db7f052cdcb9fd5b996e2f9cb7c513%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2919716808&rft_id=info:pmid/33786285&rfr_iscdi=true